Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis

Zhi-Kang Ye1,2, Hui-Lin Tang1, Suo-Di Zhai1*

1 Department of Pharmacy, Peking University Third Hospital, Beijing, China, 2 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China

Abstract

Background and Objective: The necessity of therapeutic drug monitoring (TDM) for vancomycin is controversial. The objective of the current review was to evaluate the available evidence for the necessity of TDM in patients given vancomycin to treat Gram-positive infections.

Methods: Medline, Embase, Web of Sciences, the Cochrane Library and two Chinese literature databases (CNKI, CBM) were searched. Randomized controlled studies and observational studies that compared the clinical outcomes of TDM groups vs. non-TDM groups were included. Two reviewers independently extracted the data. The primary outcome was clinical efficacy of therapy. Secondary outcomes included vancomycin associated nephrotoxicity, duration of vancomycin therapy, length of hospital stay, and mortality. Meta-analysis was performed using the Mantel-Haenszel fixed effect method (FEM). Odds ratios (ORs) or weighted mean differences (WMD) with 95% confidence intervals (95%CIs) were calculated for categorical and continuous outcomes, respectively.

Results: One randomized controlled trial (RCT) and five cohort studies were included in the meta-analysis. Compared with non-TDM groups, TDM groups had significantly higher rates of clinical efficacy (OR = 2.62, 95%CI 1.34–5.11 P = 0.005) and decreased rates of nephrotoxicity (OR = 0.25, 95%CI 0.13–0.48 P < 0.0001). Subgroup analyses showed that TDM group had significantly higher rates of clinical efficacy in both cohort studies subgroup (OR = 3.04, 95%CI 1.34–6.90) and in Asian population subgroup (OR = 3.04, 95%CI 1.34–6.90). TDM group had significantly decreased rates of nephrotoxicity in all subgroup. There was no significant difference in duration of vancomycin therapy (WMD = −0.40, 95%CI −2.83–2.02 P = 0.74) or length of stay (WMD = −1.01, 95%CI −7.51–5.49 P = 0.76) between TDM and non-TDM groups. Subgroup analyses showed there were no differences in duration of vancomycin therapy. Only one study reported mortality rates.

Conclusions: Studies to date show that TDM significantly increases the rate of clinical efficacy and decreases the rate of nephrotoxicity in patients treated with vancomycin.

Introduction

Vancomycin has been long considered the gold standard therapy for methicillin-resistant Staphylococcus aureus (MRSA) [1]. Due to the fact that the early use of vancomycin was associated with a number of adverse effects, including nephrotoxicity, infusion-related toxicities and possible ototoxicity, therapeutic drug monitoring (TDM) of vancomycin was advocated [2,3]. However, the practice of routine monitoring serum vancomycin concentrations has been the subject of intense debate for many years [4–9]. This controversy has led many hospitals to not monitor vancomycin serum concentrations, especially in developing countries. The consensus review from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, as well as the consensus review from the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring all recommended monitoring serum concentrations of vancomycin to minimize nephrotoxicity and maximize efficacy [10,11]. However, the clinical outcomes associated with vancomycin TDM have not been systematically quantified.

As clinical failure in patients with MRSA infections has been increasingly reported in recent years [12–15], higher serum vancomycin concentrations are needed to guarantee clinical efficacy. Many studies have shown that high proportions of patients do not achieve therapeutic target concentrations of vancomycin [16–26]. This could decrease the therapeutic antibacterial activity of vancomycin. We hypothesize that vancomycin TDM would allow a greater proportion of patients to achieve therapeutic target concentrations of vancomycin in the serum and increase clinical efficacy.

The objective of this systematic review and meta-analysis was to evaluate the available evidence regarding the benefits of vancomycin TDM in patients treated with vancomycin for Gram-positive infections.
Methods

Search Strategy
Published articles and conference abstracts (until March 29, 2013) that reported the clinical outcomes of monitoring vancomycin serum concentrations were identified through computerized literature searches in Pubmed, Embase, the Web of Sciences, the Cochrane Library, and two Chinese literature databases (CNKI, CBM). References of retrieved articles were also searched for additional studies. The search terms were the combination of text free terms and Medical Subject Headings (MeSH) terms as follow: ("vancomycin"MeSH) and ("therapeutic drug monitoring" OR "TDM" OR "drug monitoring" OR "therapeutic monitoring" OR "serum concentration monitoring" OR "therapeutic drug" OR "drug monitoring"MeSH). No restriction on language was applied.

Selection Criteria
Two reviewers (Z.K.Y and H.L.T) independently searched the literature and examined the relevant studies for further assessment of data. Each reviewer was blinded to the other reviewer in the process of data extraction. In case of disagreement between the two reviewers, a third reviewer (S.D.Z) was consulted. Both randomized controlled trials (RCTs) and observational studies comparing clinical outcomes of TDM and non-TDM in patients treated with vancomycin were eligible. Reviews, editorials, guidelines, case reports, and studies focusing only on pharmacokinetics and pharmacodynamics were excluded

Data extraction and outcomes
Data was extracted from the identified studies included the author, year of study and publication, country in which the study was conducted, study design, number of patients enrolled, population characteristics (type and etiology of infection), clinical efficacy, overall mortality, nephrotoxicity, duration of vancomycin therapy, and length of hospital stay. The primary outcome of the review was clinical efficacy. This was generally defined in the individual studies as absence of symptoms and signs and successful eradication of the causative pathogens. Secondary outcomes were duration of vancomycin therapy, length of stay, mortality and nephrotoxicity. Nephrotoxicity was defined as a rise in serum creatinine concentration (SCr) of greater than 44 umol/L (0.5 mg/dl) or 50% greater than the baseline during vancomycin therapy.

Quality appraisal
Two authors (Z.K.Y and H.L.T) independently assessed the quality of the studies. Discrepancies were resolved by discussion or

Figure 1. Flow chart depicting the selection process of studies included in the meta-analysis.
doi:10.1371/journal.pone.0077169.g001
| Reference | Design, years, country | Setting | Type of infection | Pathogens | Number of patients | Nephrotoxicity definition | Mean age (yr) | Gender (male/female) | Renal function | Weight (kg) |
|-----------|------------------------|---------|------------------|-----------|-------------------|--------------------------|---------------|---------------------|---------------|------------|
| Weilty 1994 [30] | PrC, SC, 1990–1991, United States | Tertiary-care, teaching hospital | NR | NR | 61 | Increase in CREA\(^a\) of greater than 0.5 mg/dl | 58±17 | 55±19 | 40/21 | 32/23 | NR | NR | 75.7±20.9 | 70.5±17 |
| Fernandez de Gatta 1996 [31] | RCT, SC, Spain | NR | Empirical treatment, febrile patients with hematological malignancies with persistent fever more than 72 h | A strong suspicion of infection caused by gram-positive organisms | 37 | Increase in CREA\(^a\) of greater than 0.5 mg/dl. Mild: 0.5–0.9, Moderate: 1.0–2.4, Severe: greater than 2.5 mg/dl | 50.2±18.7 | 56.3±13.7 | 29/8 | 21/12 | 0.88±0.31 (mg/dl) | 0.83±0.25 (mg/dl) | 62.0±112.6 | 65.7±120.0 |
| Iwamoto 2003 [32] | ReC, SC, 1996–2002, Japan | NR | Pneumonia, bacteremia and other infections | MRSA | 73 | Increase in CREA\(^a\) of greater than 0.3 mg/dl. Classify into three categories: greater than 0.3–0.5 mg/dl, 0.6–0.9 mg/dl and 1 mg/dl | 51.8±25.8 | 53.3±23.1 | 48/25 | 73/38 | 59.6±16.3 (ml/min) | 60.4±19.5 (ml/min) | NR | NR |
| Sato 2007 [33] | PrC, 2003–2006, Japan | All | MRSA | 48 | NR | NR | NR | NR | NR | NR | NR | NR |
| Mochizuki 2010 [34] | ReC, SC, 2006–2009, Japan | Catheter related bloodstream infections | CNS | 12 | 8 | Increase in CREA\(^a\) of greater than 0.5 mg/dl or 50% greater than the baseline | 53.8±19.6 | 64.3±7.7 | 9/3 | 6/2 | 0.71±0.26 (mg/dl) | 0.72±0.09 (mg/dl) | 52.8±126.0 | 49.5±11.3 |
| Huang 2011 [35] | PrC, SC, 2007–2010, China | Bloodstream infection, pneumonia, urinary tract infection, Skin and soft tissue infection | MRSA, MRCNS | 18 | 34 | Increase in CREA\(^a\) of greater than 0.5 mg/dl or 50% greater than the baseline | 52±18 | 51±19 | 10/8 | 21/13 | 86.1±35.2 (umol/L) | 83.8±31.9 (umol/L) | 64±11 | 67±10 |

\(^a\) a rise during vancomycin therapy.
\(^b\) a rise was found more than two consecutive times after 3 days of vancomycin therapy.
\(^c\) a rise was found more than two consecutive times after several days of vancomycin therapy.

doi:10.1371/journal.pone.0077169.t001
through consultation with the third reviewer (S.D.Z). The following risks of bias in RCTs were assessed, according to the criteria developed by the Cochrane risk of bias tool: random sequence generation and concealment of allocation; blinding of participants and personnel; blind assessment of outcomes; incomplete outcomes data; selective outcome reporting and other bias. The quality of observational studies was assessed using the NewCastle-Ottawa scales [27].

Table 2. Quality appraisal of observational studies (indicators from New-Castle-Ottawa scale).

| References            | Quality indicators | 1a | 2b | 3c | 4d | 5A* | 5B† | 6§ | 7‖ | 8‖ |
|-----------------------|--------------------|----|----|----|----|-----|-----|----|----|----|
| Welty 1994 [30]       | selected group     | Yes| Yes| Yes| No | yes | yes | yes| NR |
| Iwamot 2003 [32]      | yes                | Yes| Yes| Yes| Yes| Yes | yes | yes| NR |
| Sato 2007 [33]        | yes                | Yes| Yes| Yes| No | No  | yes | yes| NR |
| Mochizuki 2010 [34]   | selected group     | Yes| Yes| Yes| No | Yes | yes | yes| NR |
| Huang 2011 [35]       |                    | Yes| Yes| Yes| Yes| Yes | yes | yes| NR |
| NR, not reported.     |                    |    |    |    |    |     |     |    |    |
| aIndicates exposed cohort truly representative. |              |    |    |    |    |     |     |    |    |
| bNon-exposed cohort drawn from the same community. |              |    |    |    |    |     |     |    |    |
| cAscertainment of exposure from a secure record. |              |    |    |    |    |     |     |    |    |
| dOutcome of interest not present at start of study. |              |    |    |    |    |     |     |    |    |
| eCohorts comparable on basis of site and etiology of infection. |              |    |    |    |    |     |     |    |    |
| fCohorts comparable on other factors. |              |    |    |    |    |     |     |    |    |
| gAssessment of outcome of record linkage or independent blind assessment. |    |    |    |    |     |     |    |    |
| hFollow-up long enough for outcomes to occur. |              |    |    |    |    |     |     |    |    |
| iComplete accounting for cohorts. |              |    |    |    |    |     |     |    |    |

doi:10.1371/journal.pone.0077169.t002

Figure 2. Odds ratios of clinical efficacy: TDM versus non-TDM. Test of clinical efficacy for overall effect: $Z = 2.82$ $P = 0.005$; test of clinical efficacy in cohort studies for overall effect: $Z = 2.65$ $P = 0.008$; test of clinical efficacy in RCT for overall effect: $Z = 1.12$ $P = 0.265$.

doi:10.1371/journal.pone.0077169.g002
All statistical analyses were conducted in STATA 12.0. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for categorical outcomes (clinical efficacy and nephrotoxicity) using the Mantel-Haenszel fixed-effects models because there was no evidence of significant heterogeneity for these outcomes. Pooled weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated for continuous outcomes (duration of vancomycin therapy and length of hospital stay) using inverse variance fixed effects models if no significant heterogeneity was present. Otherwise random effects models were used. Subgroup analyses were conducted according to the study design (RCT or Cohort studies) and geographic location of patients (Asian population or non-Asian population). Heterogeneity among studies was assessed using X² test for heterogeneity and quantified using the Higgins I². To account for the low statistical power of the X² test for heterogeneity, P<0.1 was considered significant. If the P<0.1 or I² more than 50%, a sensitivity analysis was conducted to assess the validity of outcomes. Publications bias was assessed by the Begg funnel plot and the Egger’s test. Benefits of Vancomycin Therapeutic Drug Monitoring

Figure 3. Odds ratios of nephrotoxicity (subgroup analysis by design): TDM versus non-TDM. Test of nephrotoxicity for overall effect: Z = 4.17 P<0.001; test of nephrotoxicity in cohort studies for overall effect: Z = 3.31 P = 0.001; test of nephrotoxicity in RCT for overall effect: Z = 2.60 P = 0.009.
doi:10.1371/journal.pone.0077169.g003

Statistical analysis
All statistical analyses were conducted in STATA 12.0. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for categorical outcomes (clinical efficacy and nephrotoxicity) using the Mantel-Haenszel fixed-effects models because there was no evidence of significant heterogeneity for these outcomes. Pooled weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated for continuous outcomes (duration of vancomycin therapy and length of hospital stay) using inverse variance fixed effects models if no significant heterogeneity was present. Otherwise random effects models were used. Subgroup analyses were conducted according to the study design (RCT or Cohort studies) and geographic location of patients (Asian population or non-Asian population). Heterogeneity among studies was assessed using X² test for heterogeneity and quantified using the Higgins I². To account for the low statistical power of the X² test for heterogeneity, P<0.1 was considered significant. If the P<0.1 or I² more than 50%, a sensitivity analysis was conducted to assess the validity of outcomes. Publications bias was assessed by the Begg funnel plot and the Egger’s test (28,29).

Results
Figure 1 shows the study selection process for inclusion in the meta-analysis. We initially identified 1233 potentially relevant studies. A total of 1156 were excluded after review of the titles; 456 were duplicate articles, 632 were not relevant and 68 were not clinical trials or cohort studies. The full-text articles of the remaining 77 studies were evaluated. Another 71 studies were excluded because they did not meet inclusion criteria. Among these, 37 of the studies did not compare the clinical outcomes between the TDM group and the non-TDM group, 29 studies focused only on the pharmacokinetics or pharmacodynamics of vancomycin (n = 29), 4 studies were cost effectiveness studies, and the fulltext could not be obtained from 1 study even after contacting the corresponding author. Six studies were ultimately included in the meta-analysis (30–35). These studies included a total of 521 patients; 249 managed with TDM and 272 managed without TDM.

Study description
A summary description of the included studies is reported in Table 1. All studies reported on patients treated between 1990 and 2010. Of these, three studies were conducted in Japan, one study in the United States, one study in Spain, and the last in China. Five studies were cohort studies, and one study was a RCT. Welty et al. [30] did not report the type of infection and pathogens. Iwamoto et al. [32] compared the incidence of nephrotoxicity and the duration of vancomycin therapy between the TDM group (n = 77) and the non-TDM group (n = 111). Patients with pneumonia or bacteremia in both the TDM (n = 53) and the non-TDM groups (n = 46) were extracted and compared. In this
study, nephrotoxicity was defined as a rise in Scr of greater than 0.3 mg/dl. Nephrotoxicity was classified into three categories: (1) a rise in Scr of greater than 0.3–0.5 mg/dl; (2) a rise in Scr of greater than 0.6–0.9 mg/dl; (3) a rise in Scr of greater than 1 mg/dl. We excluded patients with a rise in Scr of greater than 0.3–0.5 mg/dl and only included patients with a rise in Scr of greater than 0.5 mg/dl when we conduct statistical analysis about nephrotoxicity. Sato et al. [33] did not report the definition of nephrotoxicity.

Quality of included studies

The method used to generate the allocation sequence in the RCT was considered adequate, whereas allocation concealment was not described. Baseline measurements and characteristics were provided and were similar between TDM and non-TDM groups. Withdrawn patients were reported. Evaluation of the study subjects was by an independent investigator who was blinded to their group assignment.

Table 2 shows the quality appraisal of included cohort studies. Two studies were adequate in 8 of the 9 factors assessed, and three were adequate in 6 of the 9. None of the studies completely accounted for the cohorts.

Primary outcomes

Clinical efficacy. Four studies reported the primary outcome: rates of clinical efficacy [31,33–35]. Compared with the non-TDM group, the TDM group had a significantly higher rate of clinical efficacy (OR = 2.62, 95% CI 1.34–5.11, P = 0.005; Figure 2). Subgroup analyses showed that TDM group had a significantly higher rate of clinical efficacy in cohort studies subgroup (OR = 3.04, 95% CI 1.34–6.90, P = 0.008; Figure 2) and in Asian population subgroup (OR = 3.04, 95% CI 1.34–6.90, P = 0.008; Figure 2). Only one study in RCT subgroup and in non-Asian population subgroup (OR = 1.94, 95% CI 0.61–6.20, P = 0.26; Figure 2). No significant heterogeneity was found among the studies (I² = 0%, P = 0.52).

Secondary outcomes

Nephrotoxicity. Five of six studies reported rates of nephrotoxicity [30–32,34,35]. Compared with the non-TDM group, the TDM group had a significantly decreased risk of nephrotoxicity (OR = 0.25, 95% CI 0.13–0.48, P = 0.0001). Subgroup analyses showed that TDM group had a significantly decreased risk of nephrotoxicity in cohort studies subgroup (OR = 0.27, 95% CI 0.12–0.58, P = 0.001; Figure 3) and in RCT subgroup (OR = 0.21, 95% CI 0.07–0.68, P = 0.009; Figure 3). TDM group had a significantly decreased risk of nephrotoxicity in Asian population subgroup (OR = 0.30, 95% CI 0.11–0.84, P = 0.022; Figure 4) and in non-Asian population subgroup (OR = 0.22, 95% CI 0.10–0.51, P = 0.0004; Figure 4). No significant heterogeneity was found among the studies (I² = 0%, P = 0.60).
Duration of vancomycin therapy. Four of six studies reported data on the duration of vancomycin therapy [30–32,34]. There was significant heterogeneity among these studies ($I^2 = 58\%$, $P = 0.07$). Based on a random effects model, there were no significant differences in the mean duration of therapy in the two groups ($WMD = -0.40$, 95%CI $-2.83$ to $2.02$, $P = 0.74$) (Figure 5). Subgroup analyses showed that there were no significant differences in cohort studies subgroup ($WMD = -0.32$, 95%CI $-3.31$ to $2.67$, $P = 0.83$; Figure 5), in RCT subgroup ($WMD = -1.30$, 95%CI $-5.49$ to $2.89$, $P = 0.54$; Figure 5), in Asian population subgroup ($WMD = 0.52$, 95%CI $-2.72$ to $3.75$, $P = 0.75$; Figure 6) and in non-Asian population subgroup ($WMD = -1.84$, 95%CI $-4.68$ to $1.01$, $P = 0.21$; Figure 6). The sensitivity analysis of studies evaluating duration of vancomycin therapy showed a high level of robustness (Figure S1).

Length of hospital stay. Two of six studies reported length of hospital stay [30,31]. The length of stay for TDM group was not significantly shorter compared with the non-TDM group ($WMD = 1.01$, 95%CI $-5.49$ to $2.89$, $P = 0.76$). There was no significant heterogeneity between these studies ($I^2 = 0\%$, $P = 0.35$) (Figure 7).

Mortality. Only one study provided overall mortality rates of the TDM groups and non-TDM groups and showed that two deaths occurred in TDM group ($n = 37$) in TDM group and six deaths occurred in non-TDM group ($n = 33$) [31].

Figure 5. Weight Mean Difference of Duration of vancomycin therapy (subgroup analysis by design): TDM versus non-TDM. Test of duration of vancomycin therapy for overall effect: $Z = 0.33$ $P = 0.74$; test of duration of vancomycin therapy in cohort studies for overall effect: $Z = 0.21$ $P = 0.83$; test of duration of vancomycin therapy in RCT for overall effect: $Z = 0.61$ $P = 0.54$.
doi:10.1371/journal.pone.0077169.g005

Publication bias
Publication bias were not detected for studies evaluating clinical efficacy (Begg’s test $P = 1.000$, Egger’s test $P = 0.944$), nephrotoxicity (Begg’s test $P = 0.462$, Egger’s test $P = 0.669$) and duration of vancomycin therapy (Begg’s test $P = 0.308$, Egger’s test $P = 0.130$). Studies that evaluated length of hospital stay and mortality rate were inadequate for the assessment of publication bias.

Discussion
This meta-analysis of prior studies indicates that TDM is associated with significantly higher rates of clinical efficacy and lower rates of nephrotoxicity in patients treated with vancomycin for infections with Gram-positive organisms. Subgroup analyses also showed that TDM is associated with significantly higher rates of clinical efficacy and lower rates of nephrotoxicity. There were not enough data to evaluate the clinical efficacy in RCT subgroup and non-Asian population subgroup. The higher rates of clinical efficacy in the TDM groups is probably due to the fact that a higher proportion of patients had managed with TDM achieved vancomycin serum concentrations in therapeutic range. The lower rate of nephrotoxicity in the TDM is likely due to a lower proportion of patients with supratherapeutic serum concentrations of vancomycin. Vancomycin TDM can significantly decreased the rate of nephrotoxicity in Asian population and non-Asian population, which showed this effect did not dependent on geographic location of patients.
We found no significant differences in the duration of vancomycin therapy in between TDM patients and non-TDM patients, even though there was a tendency to decrease duration of vancomycin therapy. All subgroup analyses also showed that there were no significant differences in between TDM group and non-TDM group. The reason probably could be is that a high proportion of patients still did not reach the therapeutic concentration and the TDM may have started is too late in the TDM group. Iwamoto [32] reported that half of the patients in the TDM group did not reach a therapeutic concentration of vancomycin within 10 days of initial therapy and that it often took more than 10 days to reach therapeutic concentrations. This is detrimental since maximizing the effects of vancomycin is vitally important when treating MRSA infections. The time it takes to achieve the target concentration of vancomycin may be associated with the duration of vancomycin therapy and clinical outcomes [36].

To our knowledge, this is the first meta-analysis that supports vancomycin TDM to increase clinical efficacy and decrease nephrotoxicity. One prior systematic review [37] included two studies and showed no differences in clinical efficacy and nephrotoxicity. We did not assess hospital costs in our studies, although previous research has shown that there is a difference in hospital cost when comparing TDM and non-TDM groups. Darko et al [5] calculated the cost of preventing one vancomycin associated nephrotoxicity episode through TDM to be $8363 for intensive care patients, $5000 for oncology patients and $5564 for patients receiving concomitant nephrotoxins. Similarly, Fernandez de Gatta et al [31] calculated the cost of preventing one mild or moderate vancomycin associated nephrotoxicity to be $435 and $1307, respectively. The results of these two studies indicate that TDM of vancomycin is probably cost-effective, with the biggest potential savings from intensive care patients, oncology patients and patients receiving concomitant nephrotoxins.

Not enough data was available for our meta-analysis to assess which group of patients needed vancomycin TDM the most. However, it should be noted that some special types of patients probably need vancomycin TDM more than others. Some studies have shown wide inter-patient variability in vancomycin pharmacokinetics among adults [38], especially in critically ill patients, patients with severe sepsis, patients undergoing continuous venovenous hemodialysis, cancer patients, neonatal patients, and patients with severe burn injuries [39–46].

We used a comprehensive search strategy to identify the largest number of studies possible. There are also limitations that should be considered when managing our results. First, a relatively small number of studies were included and one is a RCT. However, there was no significant heterogeneity associated with most outcomes, suggesting consistency of results, and most of the studies were adequate in the majority of quality variables evaluated. Second, only one study reported the rates of mortality.

In conclusion, our meta-analysis of prior studies indicate that TDM of vancomycin is associated with higher rates of clinical

![Figure 6. Weight Mean Difference of Duration of vancomycin therapy (subgroup analysis by geographic location of patients): TDM versus non-TDM. Test of duration of vancomycin therapy for overall effect: Z = 0.33 P = 0.74; test of duration of vancomycin therapy in Asian population subgroup for overall effect: Z = 0.31 P = 0.75; test of duration of vancomycin therapy in non-Asian population subgroup for overall effect: Z = 1.27 P = 0.21. doi:10.1371/journal.pone.0077169.g006](image)
efficacy and lower rates of nephrotoxicity in patients with Gram-positive organism infections. Based on our findings, we recommend routine monitoring of serum vancomycin concentrations. This may be particularly useful for patients at the greatest risk of altered vancomycin pharmacokinetics.

Supporting Information

Figure S1 Sensitivity analysis of duration of vancomycin therapy. (EPS)

Table S1 PRISMA checklist of this meta-analysis. (DOC)

Acknowledgments

We thank all of the members of our study team for their whole-hearted cooperation and the original authors of the included studies for their wonderful work.

Author Contributions

Conceived and designed the experiments: ZKY SDZ. Performed the experiments: ZKY HLT. Analyzed the data: ZKY HLT. Contributed reagents/materials/analysis tools: ZKY HLT. Wrote the paper: ZKY. Revised the manuscript: ZKY HLT SDZ. Approved the final version of the manuscript: ZKY HLT SDZ.

References

1. Cataldi MA, Tacconelli E, Grilli E, Pea F, Petrosillo N (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67: 17–24.
2. Moellering RC, Jr. (2006) Vancomycin: a 50-year reassessment. Clin Infect Dis 42 Suppl 1: S3–4.
3. Levine DP (2006) Vancomycin: a history. Clin Infect Dis 42 Suppl 1: S5–12.
4. Rybak MJ (2006) The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 Suppl 1: S35–39.
5. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE (2003) Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 23: 643–650.
6. Cantu TG, Yamanaka-Yuen NA, Liezman PS (1994) Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 18: 533–543.
7. Karachalios GN, Tziviskou EM (1998) Vancomycin: Is it necessary the therapeutic drug monitoring? Epitheorese Klinikes Farmakologias kai Farmakokinetikes 16: 110–119.
8. Pryka RD (1994) Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother 28: 1397–1399.
9. Moellering RC, Jr. (1994) Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 18: 544–546.
10. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr., Craig W, et al. (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82–98.
11. Matsumoto K, Takesue Y, Ohmaeari N, Mochizuki T, Mikamo H, et al. (2013) Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother.
12. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, et al. (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38: 521–528.
13. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, et al. (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315–3320.
14. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr., et al. (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42: 2398–2402.
Benefits of Vancomycin Therapeutic Drug Monitoring

15. Hidavat LK, Hu DI, Quist R, Shinier KA, Wong-Berenger A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166: 2130–2144.

16. De Cock P, Hargeman E, Goerlandt N, Vanhaeckebruck P, Steve V, et al. (2010) Focused Conference Group: P13 - Maximising benefits and minimizing harms from drug vancomycin dosing and monitoring in children: Compliance with guidelines in a belgian teaching hospital. Basic Clin Pharmacol 107: 250–251.

17. Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA (2012) Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents 39: 69–72.

18. Khotaei GT, Jam S, SeyedAlinaghi S, Motamed F, Nejat F, et al. (2010) Vancomycin: the need to suit serum concentrations in hemodialysis patients with normal renal function. Acta Medica Irannica 48: 91–94.

19. Mariani-Kurkdjian P, Nebblil H, Anjard Y, Bingen E (2008) [Monitoring serum vancomycin concentrations in the treatment of Staphylococcus infections in children]. Arch Pediatr 15: 1623–1629.

20. Commandeur D, Giaraggi C, Dangay Des Manges M, Huys S, Buguet-Brown ML, et al. (2011) [Monitoring vancomycin in an intensive care unit: A retrospective survey on 66 patients]. Med Mal Infect 41: 410–414.

21. Reis AGAC, Guri SFFE (1996) Monitoring of blood levels of vancomycin in children with multi-resistant bacterial infections. Jornal de Pediatría 72: 225–229.

22. Pea F, Poir D, Baraldo M, Furlanut M (2000) Optimisation of vancomycin regimens in neutropenic haematological patients with normal renal function - Multiple daily doses may be preferable. Clin Drug Invest 19: 213–218.

23. Miles MV, Li L, Lakki H, Younghood J, McGinnis P (1997) Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia. Med Mal Infect 41: 652–656.

24. Eiland LS, English TM, Eiland EH, (2011) Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother 45: 502–509.

25. Wells GS, Shea B, O’Connell D, Peterson J, Welch V, et al. (2005) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (20 April 2013, data last accessed).

26. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.

27. Miles MV, Li L, Lakki H, Younghood J, McGinnis P (1997) Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia. Med Mal Infect 41: 652–656.

28. Jeffres MN, Eakin S, Sehrin KA, McKinnon PS, Ritchie DJ, et al. (2006) Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130: 947–955.

29. Zhang C, Zhai SD, Liu F (2009) Necessity of therapeutic drug monitoring of vancomycin in clinical use: a systematic review. Chin J Clin Pharmacol 25: 329–333.

30. Al-Kofide H, Zaghloul I, Al-Naim L (2010) Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther 48: 140–145.

31. Fernandez de Gatta MD, Calvo MV, Hernandez JF, et al. (1996) Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 60: 332–340.

32. Iwamoto T, Kagawa Y, Kojima M (2003) Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26: 876–879.

33. Sato S, Sato Y (2007) Evaluation of the usefulness of vancomycin dosage design based on pharmacokinetics/pharmacodynamics theory. Jpn J Chemother 55: 220–224.

34. Mochizuki T, Sato T, Okinaka K, Kishida N, Fujita T, et al. (2010) Efficacy and safety for vancomycin in uncomplicated catheter-related bloodstream infection by coagulase negative Staphylococcus. Jpn J Chemother 58: 233–238.

35. Huang YZ, Mao MY, Yuan KK (2011) Clinical application of drug monitoring of vancomycin. Chin J Infect Chemother 11: 293–298.

36. Mochizuki T, Sato T, Kishida N, Fujita T, et al. (2010) Efficacy and safety for vancomycin in uncomplicated catheter-related bloodstream infection by coagulase negative Staphylococcus. Jpn J Chemother 58: 233–238.

37. Huang YZ, Mao MY, Yuan KK (2011) Clinical application of drug monitoring of vancomycin. Chin J Infect Chemother 11: 293–298.

38. Pea F, Porreca L, Baraldo M, Furlanut M (2000) High vancomycin dosing regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 45: 329–333.

39. Al-Kofide H, Zaghloul I, Al-Naim L (2010) Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract 16: 245–250.

40. Badran EF, Shamayleh A, Irshaid YM (2011) Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther 49: 252–257.

41. Golestaneh L, Gofran A, Mokrzycki MH, Chen JL (2009) Removal of vancomycin from dialysate. Clin Nephrol 72: 286–291.

42. Huang YZ, Mao MY, Yuan KK (2011) Clinical application of drug monitoring of vancomycin. Chin J Infect Chemother 11: 293–298.

43. Mochizuki T, Sato T, Kishida N, Fujita T, et al. (2010) Efficacy and safety for vancomycin in uncomplicated catheter-related bloodstream infection by coagulase negative Staphylococcus. Jpn J Chemother 58: 233–238.